Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 901-905

  Emmons, Gary T ^a   Argenti, Rick ^a   Martin, Louis L ^a   Martin, Nancy E ^a   Jensen, Bradford K ^a  

^a SANOFI   (France)

Author keywords

Angiotensin converting enzyme neutral endopeptidase (ACE NEP) inhibitor; Elderly; Hypertension; M100240; MDL 100,173; Pharmacokinetics

Indexed keywords

1,2,3,4,6,7,8,12B OCTAHYDRO 7 (2 MERCAPTO 3 PHENYLPROPIONAMIDO) 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR;

ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; BENZAZEPINES; FEMALE; HALF-LIFE; HUMANS; MALE; NEPRILYSIN; PRODRUGS; PYRIDINES;

EID: 3242741988     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004267588     Document Type: Article

References (3)

1. French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, et al: Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-186.
2. Ren Y, Martin LL, Emmons GT, Zheng W, Jenkins RG, Huang Y: Quantitative determination of M100240 and its metabolite, MDL 100,173 (an ACE/NEP inhibitor), in human plasma by liquid chromatography-tandem mass spectrometry. Paper presented at the 224th ACS National Meeting, Boston, August 18-22, 2002.
3. 14C]M100240, a dual ACE/NEP inhibitor in healthy male subjects. Paper presented at the meeting of the American Association of Pharmaceutical Scientists, Toronto, Canada, November 10-14, 2002.